Felipe Andreiuolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3625511/publications.pdf

Version: 2024-02-01

516710 713466 24 727 16 21 citations g-index h-index papers 25 25 25 1090 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Coâ€occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathology, 2018, 28, 103-111.	4.1	80
2	Childhood supratentorial ependymomas with <i>YAP1â€MAMLD1</i> fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathology, 2019, 29, 205-216.	4.1	75
3	Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro-Oncology, 2016, 18, 919-927.	1.2	68
4	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nature Communications, 2019, 10, 3914.	12.8	65
5	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathology, 2019, 29, 325-335.	4.1	55
6	Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma. Journal of Neuropathology and Experimental Neurology, 2016, 75, 971-980.	1.7	54
7	Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion. Acta Neuropathologica Communications, 2015, 3, 85.	5.2	46
8	Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathologica, 2021, 141, 455-466.	7.7	37
9	YAP1/TAZ drives ependymoma-like tumour formation in mice. Nature Communications, 2020, 11, 2380.	12.8	32
10	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica, 2020, 140, 405-407.	7.7	30
11	Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. Journal of Neuroradiology, 2018, 45, 316-322.	1.1	26
12	GFAPδ immunostaining improves visualization of normal and pathologic astrocytic heterogeneity. Neuropathology, 2009, 29, 31-39.	1.2	25
13	Pediatric methylation class HGNET-MN1: unresolved issues with terminology and grading. Acta Neuropathologica Communications, 2019, 7, 176.	5.2	24
14	Constitutional mismatch repair deficiency–associated brain tumors: report from the European C4CMMRD consortium. Neuro-Oncology Advances, 2019, 1, vdz033.	0.7	23
15	Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta Neuropathologica Communications, 2021, 9, 135.	5. 2	21
16	H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components. Acta Neuropathologica Communications, 2019, 7, 78.	5.2	20
17	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. PLoS ONE, 2017, 12, e0178351.	2.5	15
18	Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome. Child's Nervous System, 2020, 36, 2693-2700.	1.1	14

#	Article	IF	CITATIONS
19	Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children. Neuro-Oncology, 2020, 22, 1686-1695.	1.2	14
20	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. Neuro-Oncology, 2019, 21, ii82-ii82.	1.2	2
21	TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICS—THE PROSPECTIVE MNP2.0 STUDY. Neuro-Oncology, 2018, 20, i181-i181.	1.2	0
22	EPEN-27. CDKN2A DELETION IN SUPRATENTORIAL EPENDYMOMA WITH RELA ALTERATION INDICATES A DISMAL PROGNOSIS â€" A RETROSPECTIVE ANALYSIS OF THE HIT EPENDYMOMA TRIAL COHORT. Neuro-Oncology, 2020, 22, iii313-iii313.	1.2	0
23	PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORS—THE MNP 2.0 STUDY. Neuro-Oncology, 2020, 22, iii426-iii426.	1.2	0
24	EPEN-24. Biological markers of ependymoma in children and adolescents (BIOMECA): Systematic comparison of methods for the precise evaluation of biomarkers for ependymoma diagnosis and prognostication. Neuro-Oncology, 2022, 24, i44-i44.	1.2	0